FirstWord

SCB-1022 and SCB-1033 generated robust antibody responses and slashed respiratory tract infection rates in older adults.

The company-initiated withdrawal was prompted by the KRAS G12C inhibitor's failure in the confirmatory KRYSTAL-10 trial.

The Phase III Lp(a)HORIZON trial evaluated whether lowering levels of lipoprotein(a) improved cardiovascular outcomes.

Etcamah (camizestrant) was granted an accelerated approval even though the agency's advisory panel voted against the drug's biomarker-driven switching strategy.

The biotech wants to take a selective M4 drug called NS-136 into Phase II schizophrenia and Alzheimer's agitation trials, and advance two other candidates as well.

WALTHAM, Mass., Sept. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROI...

AUSTIN, Texas, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines in orphan pulmonary and ...

Largest randomized individual patient-data analysis to date evaluating 1- versus 12-month dual antiplatelet therapy exclusively in patients with acute myocardial infarction (3,966 patients) Major blee...

SHANGHAI, Sept. 4, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced the Phase Ib/IIa clinical result...

- Oral Presentation in Session VI: Hereditary AngioedemaSHANGHAI and NEW YORK, Sept. 4, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (...